BR112022020974A2 - Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk - Google Patents

Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk

Info

Publication number
BR112022020974A2
BR112022020974A2 BR112022020974A BR112022020974A BR112022020974A2 BR 112022020974 A2 BR112022020974 A2 BR 112022020974A2 BR 112022020974 A BR112022020974 A BR 112022020974A BR 112022020974 A BR112022020974 A BR 112022020974A BR 112022020974 A2 BR112022020974 A2 BR 112022020974A2
Authority
BR
Brazil
Prior art keywords
respiratory distress
acute respiratory
syndrome
distress syndrome
treatment
Prior art date
Application number
BR112022020974A
Other languages
English (en)
Portuguese (pt)
Inventor
Langrish Claire
Thomas Dolca
Wolff Stefani
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of BR112022020974A2 publication Critical patent/BR112022020974A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112022020974A 2020-04-22 2021-04-21 Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk BR112022020974A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063013784P 2020-04-22 2020-04-22
PCT/US2021/028381 WO2021216696A1 (en) 2020-04-22 2021-04-21 Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using btk inhibitors

Publications (1)

Publication Number Publication Date
BR112022020974A2 true BR112022020974A2 (pt) 2022-12-06

Family

ID=75919390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020974A BR112022020974A2 (pt) 2020-04-22 2021-04-21 Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk

Country Status (12)

Country Link
US (1) US20230158031A1 (enExample)
EP (1) EP4138836A1 (enExample)
JP (2) JP2023522693A (enExample)
KR (1) KR20230015346A (enExample)
CN (1) CN115443136A (enExample)
AU (1) AU2021261327A1 (enExample)
BR (1) BR112022020974A2 (enExample)
CA (1) CA3175788A1 (enExample)
IL (1) IL297316A (enExample)
MX (1) MX2022013164A (enExample)
TW (1) TW202206076A (enExample)
WO (1) WO2021216696A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
PL2710005T3 (pl) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
EP2773639B1 (en) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015149056A1 (en) * 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2021211782A1 (en) * 2020-04-15 2021-10-21 Telios Pharma, Inc. Methods of treating acute lung injury and acute respiratory distress syndrome

Also Published As

Publication number Publication date
AU2021261327A1 (en) 2022-12-22
WO2021216696A1 (en) 2021-10-28
CN115443136A (zh) 2022-12-06
TW202206076A (zh) 2022-02-16
JP2026027386A (ja) 2026-02-18
KR20230015346A (ko) 2023-01-31
IL297316A (en) 2022-12-01
JP2023522693A (ja) 2023-05-31
CA3175788A1 (en) 2021-10-28
MX2022013164A (es) 2022-11-30
US20230158031A1 (en) 2023-05-25
EP4138836A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
JP2024042014A5 (ja) ゲームコントローラセット、および、システム
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
BR112022018115A2 (pt) Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais
CY1114363T1 (el) Ανθελμινθικος συνδυασμος
BR112022020974A2 (pt) Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk
EA202193012A1 (ru) Способы введения определенных ингибиторов vmat2
BR112022021381A2 (pt) Compostos para o tratamento de sars
EP4277554A4 (en) MEDICAL DILATOR AND SYSTEMS, METHODS AND KITS FOR MEDICAL DILATION
CA3251244A1 (en) PI3K-ALPHA INHIBITORS AND THEIR METHODS OF USE
DK4430042T3 (da) 6-hetero-aryloxy-benzimidazoler og azabenzimidazoler som JAK2-hæmmere
MX2022012000A (es) Inhibidores de c5a para el tratamiento de infeccion por coronavirus.
LT4284512T (lt) Citokinų išsiskyrimo sindromo gydymo kompozicijos ir būdai
EP4281529A4 (en) SUSTAINABLE CANDLES AND PROCESSES
BR112022023187A2 (pt) Compostos para o tratamento da sars
PL4125843T3 (pl) Leczenie ciężkiego zespołu zapalnego
EP4556072A3 (en) Compositions for monocyte and macrophage polarization and methods of use
WO2005065668A3 (en) Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
CL2022000933A1 (es) Manejo temprano y prevención de sepsis y síndrome similar a sepsis
EP4119165A4 (en) NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME
CL2023000679A1 (es) Métodos y composiciones relacionados con la evaluación de afecciones inflamatorias relacionadas con la fecundidad
LT4110288T (lt) Vietinė kompozicija, skirta palaikyti ir (arba) atkurti gleivinės ir pažeisto epidermio vientisumą
IL311606A (en) Molluscum contagiosum infection inhibitors and methods of using them